Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey-Reference-Cited by-同舟云学术

Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey

Published:2023-05-09 Issue:8 Volume:23 Page:827-832
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Sarlós Patrícia¹²^ORCID,Bikar Alexander¹^ORCID,Farkas Nelli²,Resál Tamás³,Szepes Zoltán³^ORCID,Farkas Klaudia³^ORCID,Nagy Ferenc³,Vincze Áron¹,Miheller Pal⁴,Molnár Tamás³^ORCID

Affiliation:

1. Department of Medicine, University of Pecs Medical School, Pecs, Hungary

2. Institute for Translational Medicine, University of Pecs Medical School, Pecs, Hungary

3. Department of Medicine, University of Szeged Albert Szent-Györgyi, Szeged, Hungary

4. Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2211204

Reference33 articles.

1. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002–2006

2. The burden of inflammatory bowel disease in Europe

3. Treatment of Inflammatory Bowel Disease: A Comprehensive Review

4. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

5. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars;Frontiers in Pharmacology;2024-07-24